How have PHGUF shares performed in 2024?

Pharming Group's stock was trading at $1.1750 at the start of the year. Since then, PHGUF stock has decreased by 19.1% and is now trading at $0.95. View the best growth stocks for 2024 here .

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative net margin of 4.11% and a negative trailing twelve-month return on equity of 4.47%.

How do I buy shares of Pharming Group?

Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:PHGUF

Pharming Group (PHGUF) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free PHGUF Stock Alerts

$0.95

-0.12 (-11.21%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.95
▼
$0.95
50-Day Range: $1.07
▼
$1.29
52-Week Range: $0.95
▼
$1.40

Volume: 300 shs
Average Volume: 100 shs
Market Capitalization: $619.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Headlines Short Interest

Get Pharming Group alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Pharming Group Stock (OTCMKTS:PHGUF)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

PHGUF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHGUF Stock News Headlines

April 18, 2024 | finance.yahoo.com

Pharming Group announces the placement of €100 million convertible bonds due 2029

April 8, 2024 | markets.businessinsider.com

Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | finanznachrichten.de

Pharming Group N.V.: Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

April 4, 2024 | finance.yahoo.com

Pharming Group announces the 2024 Annual General Meeting of Shareholders

April 3, 2024 | finance.yahoo.com

Pharming Group to participate in April investor conferences

March 17, 2024 | finance.yahoo.com

Pharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

March 16, 2024 | finance.yahoo.com

Pharming Group Full Year 2023 Earnings: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 15, 2024 | markets.businessinsider.com

Pharming Group’s Strong Financial Performance and Growth Potential Merit Buy Rating

February 29, 2024 | finance.yahoo.com

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

February 20, 2024 | uk.investing.com

Pharming Group NV (PHAR)

January 12, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Pharming Group (OtherPHGUF)

January 8, 2024 | finanznachrichten.de

Pharming Group N.V.: Pharming Group announces updated full year 2023 guidance and Joenja U.S. launch update

January 8, 2024 | markets.businessinsider.com

Pharming Group Projects 2023 Total Revenues To Rise 19%

January 8, 2024 | finance.yahoo.com

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

November 21, 2023 | finance.yahoo.com

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

November 10, 2023 | finance.yahoo.com

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

November 7, 2023 | finance.yahoo.com

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

October 26, 2023 | msn.com

Pharming GAAP EPS of $0.01 beats by $0.005, revenue of $66.7M beats by $4.87M

October 12, 2023 | finanznachrichten.de

Pharming Group N.V.: Pharming Group to report third quarter 2023 financial results on October 26

October 12, 2023 | finance.yahoo.com

Pharming Group to report third quarter 2023 financial results on October 26

September 22, 2023 | finance.yahoo.com

Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?

September 9, 2023 | msn.com

Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Pharming Group (PHAR)

August 9, 2023 | markets.businessinsider.com

Pharming Group NV American Depositary Shares Repr 10 Shs Reg S

August 4, 2023 | msn.com

Pharming Group N.V. reports Q2 results

See More Headlines

Receive PHGUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2015
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:PHGUF
Previous Symbol: OTC:PHGUF
CUSIP: N/A
CIK: N/A
Web: www.pharming.com
Phone: (171) 524-7400
Fax: 31-0-71-524-7445
Employees: 332
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,550,000.00
Net Margins: -4.11%
Pretax Margin: -4.90%
Return on Equity: -4.47%
Return on Assets: -2.12%

Debt

Debt-to-Equity Ratio: 0.76
Current Ratio: 4.06
Quick Ratio: 3.33

Sales & Book Value

Annual Sales: $245.32 million
Price / Sales: 2.83
Cash Flow: $0.01 per share
Price / Cash Flow: 106.24
Book Value: $0.34 per share
Price / Book: 3.13

Miscellaneous

Outstanding Shares: 652,410,000
Free Float: N/A
Market Cap: $694.82 million
Optionable: Not Optionable
Beta: 1.07

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Sijmen de Vries M.B.A. (Age 65)
M.D., President, CEO & Executive Director
Comp: $1.18M
Mr. Jeroen Wakkerman (Age 55)
Chief Financial Officer
Ms. Mireille Sanders M.Sc. (Age 56)
Chief Operations Officer
Susanne Embleton
Investor Relations Manager
Mr. Ruud Van Outersterp (Age 60)
Chief Ethics & Compliance Officer
Dr. Anurag Relan M.D. (Age 52)
MPH, Chief Medical Officer
Mr. Stephen Toor (Age 53)
Chief Commercial Officer & GM Americas
Dr. Alexander Breidenbach M.B.A.
Chief Business Officer
Dr. Bruno M. L. Giannetti (Age 72)
Consultant

Key Competitors

View All Competitors

PHGUF Stock Analysis - Frequently Asked Questions

How have PHGUF shares performed in 2024?: Pharming Group's stock was trading at $1.1750 at the start of the year. Since then, PHGUF stock has decreased by 19.1% and is now trading at $0.95.
View the best growth stocks for 2024 here.
How were Pharming Group's earnings last quarter?: Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative net margin of 4.11% and a negative trailing twelve-month return on equity of 4.47%.
How do I buy shares of Pharming Group?: Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PHGUF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial